The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

Lenacapavir is a major step forward in HIV prevention. With just two injections a year, it is a simple and highly effective ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts say lenacapavir is easier to administer, and each dose lasts longer ...